Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
1 other identifier
observational
22
1 country
1
Brief Summary
From the medical records of a series of patients operated on for incident grade II and III glioma, the primary objective is to evaluate the correlation between the molecular profile of tumours and preoperative imaging data (by FDG and FDOPA PET-scan and multimodal MRI).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Sep 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 30, 2019
CompletedFirst Submitted
Initial submission to the registry
July 2, 2020
CompletedFirst Posted
Study publicly available on registry
July 8, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2024
CompletedJuly 3, 2024
July 1, 2024
4.8 years
July 2, 2020
July 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Primary outcome
Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
4 years
Secondary Outcomes (2)
Molecular profile
4years
Imaging data
4 years
Study Arms (1)
Cohort
Retrospective cohort
Interventions
Evaluate the correlation between tumour molecular profile and preoperative imaging data (FDG and FDOPA PET-scan and multimodal MRI).
Eligibility Criteria
The study population represents the totality of patients with a glioma surgery in the centre between February 2015 and May 2019, with a complete and usable medical file.
You may qualify if:
- Subject 18 years of age or older, having been informed of the research
- Subject operated on with an incident glioma of grade II or III, histologically confirmed (WHO 2016 classification)
- Subject for which all preoperative imaging data is available (MRI, FDG and FDOPA PET-scan)
- Subject for which molecular data of the lesion are available
You may not qualify if:
- Subject having signified his opposition to the use of his medical data
- Subject under safeguard of justice, guardianship or trusteeship
- Subject with incomplete or missing part of the molecular and/or imaging data
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hôpital Privé Clairval
Marseille, 13009, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Philippe METELLUS, MD PD
Hôpital Privé Clairval
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 2, 2020
First Posted
July 8, 2020
Study Start
September 30, 2019
Primary Completion
June 30, 2024
Study Completion
June 30, 2024
Last Updated
July 3, 2024
Record last verified: 2024-07
Data Sharing
- IPD Sharing
- Will not share